Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

BACKGROUND: Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in melanoma treatment after ICB fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Märkl, Florian, Benmebarek, Mohamed-Reda, Keyl, Julius, Cadilha, Bruno L, Geiger, Martina, Karches, Clara, Obeck, Hannah, Schwerdtfeger, Melanie, Michaelides, Stefanos, Briukhovetska, Daria, Stock, Sophia, Jobst, Jakob, Müller, Philipp Jie, Majed, Lina, Seifert, Matthias, Klüver, Anna-Kristina, Lorenzini, Theo, Grünmeier, Ruth, Thomas, Moritz, Gottschlich, Adrian, Klaus, Richard, Marr, Carsten, von Bergwelt-Baildon, Michael, Rothenfusser, Simon, Levesque, Mitchell P, Heppt, Markus Vincent, Endres, Stefan, Klein, Christian, Kobold, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201273/
https://www.ncbi.nlm.nih.gov/pubmed/37208128
http://dx.doi.org/10.1136/jitc-2022-006436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201273/
https://www.ncbi.nlm.nih.gov/pubmed/37208128
http://dx.doi.org/10.1136/jitc-2022-006436

Ejemplares similares